Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing WeMed Completes $46 Million Funding for Angiography Devices

publication date: May 6, 2021

Beijing WeMed Medical completed a $46 million Series D financing to support its digital angiography products. The company makes interventional diagnosis and treatment devices. WeMed offers products that include a digital subtraction angiography (DSA) system, a mobile angiography system, surgical C-arms, and novel R&D for interventional surgical robots  The company says its DSA products are China equivalents to machines that are already available from international device makers, but its robot products offer novel technology. The Series D round was led by Lake Bleu Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital